Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

BACKGROUND: We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers. METHODS: The study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Res...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Colen, Rivka R, Rolfo, Christian, Ak, Murat, Ayoub, Mira, Ahmed, Sara, Elshafeey, Nabil, Mamindla, Priyadarshini, Zinn, Pascal O, Ng, Chaan, Vikram, Raghu, Bakas, Spyridon, Peterson, Christine B, Rodon Ahnert, Jordi, Subbiah, Vivek, Karp, Daniel D, Stephen, Bettzy, Hajjar, Joud, Naing, Aung
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8051405/
https://ncbi.nlm.nih.gov/pubmed/33849924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001752
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados